Merck/Schering Suspend TV Ads For Vytorin, Zetia; Congress Continues To Investigate ENHANCE
This article was originally published in The Pink Sheet Daily
Executive Summary
In wake of ENHANCE study, firms launch print consumer campaign to emphasize drugs’ benefit for LDL cholesterol, Schering-Plough tells “The Pink Sheet” DAILY.
You may also be interested in...
FDA’s Change Of Heart On Vytorin Ads
Although the campaign had been running for years with no problems, FDA instructed Merck/Schering-Plough to revise the Vytorin DTC ads even as the agency publicly affirmed the utility of the drug.
FDA’s Change Of Heart On Vytorin Ads
Although the campaign had been running for years with no problems, FDA instructed Merck/Schering-Plough to revise the Vytorin DTC ads even as the agency publicly affirmed the utility of the drug.
Pfizer Pulls Plug On Controversial Lipitor Ads
Congressional probe of direct-to-consumer marketing sparks firm's change of heart on anti-cholesterol drug.